Abstract
BACKGROUND The chronic kidney disease (CKD) public health burden is substantial and has not declined as expected with current interventions on disease treatments. A large number of clinical, biological, and behavioural risk factors have been associated with CKD. However, it is unclear which of them are causal.
OBJECTIVE To systematically test whether previously reported risk factors for CKD are causally related to the disease in European and East Asian ancestries.
DESIGN Two-sample Mendelian randomization (MR) and non-linear MR analyses.
PARTICIPANTS 53,703 CKD cases and 960,624 controls of European ancestry from CKDGen, UK Biobank and HUNT, and 13,480 CKD cases and 238,118 controls of East Asian ancestry from Biobank Japan, China Kadoorie Biobank and Japan-Kidney-Biobank/ToMMo.
MEASURES Systematic literature mining of PubMed studies identified 45 clinical risk factors and biomarkers with robustly associated genetic variants, including phenotypes related to blood pressure, diabetes, glucose, insulin, lipids, obesity, smoking, sleep disorders, nephrolithiasis, uric acid, coronary artery disease, bone mineral density, homocysteine, C-reactive protein, micro-nutrients and thyroid function, which were selected as exposures. The outcome was CKD (defined by clinical diagnosis or by estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2).
RESULTS Eight risk factors showed evidence of causal effects on CKD in European ancestry, including body mass index (BMI), hypertension, systolic blood pressure, high density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein A, type 2 diabetes (T2D) and nephrolithiasis. In East Asian ancestry, BMI, T2D and nephrolithiasis showed evidence of causal effects on CKD. Hypertension showed reliable evidence of a strong causal effect on CKD in Europeans but in contrast appeared to show a null effect in East Asians, suggesting the possibility of different causal risk factors in Europeans and East Asians. Although liability to T2D showed consistent effects on CKD, the effect of glycemic traits on CKD was weak, suggesting T2D may have glucose-independent mechanisms to influence CKD. Nonlinear MR indicated a threshold relationship between genetically predicted BMI and CKD, with increased risk at BMI above 25 kg/m2.
LIMITATION Due to the unbalanced distribution of data between ancestries, we could only test 17 of the 45 risk factors in East Asian participants.
CONCLUSIONS Eight CKD-associated risk factors showed evidence of causal effects on the disease in over 1.2 million European and East Asian ancestries. These risk factors were predominantly related to cardio-metabolic health, which supports the shared causal link between cardio-metabolic health and kidney function. This study provides evidence of potential intervention targets for primary prevention of CKD, which could help reduce the global burden of CKD and its cardio-metabolic co-morbidities.
Evidence before this study Chronic kidney disease (CKD) has a major effect on global health, both as a direct cause of morbidity and mortality, and as an important complication for cardio-metabolic diseases. However, even with the existing interventions, the burden of CKD has not declined as expected over the last 30 years. Existing epidemiological studies of CKD have mainly focused on disease treatment in patients from specific populations and estimated association rather than causality. A systematic assessment of the causal determinants of CKD in different populations is urgently needed, to help promote a shift from treatment of CKD patients to prevention of the disease in high-risk groups. The use of genetic data and the latest Mendelian randomization (MR) methodologies offers a cost-effective way to evaluate the potential intervention targets for prevention of CKD in high-risk groups.
Added value of this study In this study, we systematically constructed a causal atlas of 45 risk factors on CKD in European and East Asian ancestries using MR. To maximise power of these analyses and accuracy of the findings, we collected and harmonised CKD genetic association data from six large-scale biobanks (in over 1.1 million Europeans and 250,000 East Asians). By applying a comprehensive MR framework, including linear two-sample MR, bidirectional MR, multivariable MR and non-linear MR approaches, we identified eight risk factors with reliable evidence of causal effects on CKD in European ancestry studies, including body mass index (BMI), hypertension, systolic blood pressure, high density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein A, type 2 diabetes (T2D) and nephrolithiasis. In East Asian studies, BMI, T2D and nephrolithiasis also showed causal effects on CKD. Among other factors, hypertension showed reliable evidence of a strong causal effect on CKD in Europeans but in contrast appeared to show a null effect in East Asians. This MR finding together with previous literature evidence opens up the possibility that hypertension could play different causal roles on CKD across ancestries. For diabetes and glycemic phenotypes, our MR and sensitivity analyses suggested the causal role of liability of T2D on CKD but suggested weak effects of glycemic phenotypes on CKD. This aligns with the recent trial of SGLT2 inhibitors on kidney disease, which implies T2D may have glucose-independent mechanisms to influence CKD. For lipids phenotypes, we found good evidence to support the role of high-density lipoprotein cholesterol on CKD and further suggested the effects of two lipids targets: circulating CETP level and lipoprotein A concentration. For body weight, our study quantified a threshold relationship between BMI and CKD, with increased risk at BMI above 25 kg/m2. The causal relationship between nephrolithiasis and CKD were reported in previous studies, but our study confirmed the causal links between the two for the first time.
Implication of all the available evidence This study makes a significant advance in comprehensively prioritising intervention targets for CKD in over 1.2 million participants. Our study presents causal evidence from both European and East Asian population samples, widening the generalisability of the causal atlas. Importantly, the prioritised risk factors are predominantly related to cardio-metabolic health, which supports the shared causal link between cardio-metabolic health and kidney function. Clinically, the high-quality evidence from this study highlights the value of exploring these causal factors in the general population and prioritizes drug targets and life-style interventions for CKD primary prevention, which could help reduce the global burden of CKD and its cardio-metabolic co-morbidities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JZ is funded by a Vice-Chancellor Fellowship from the University of Bristol. This research was also funded by the UK Medical Research Council Integrative Epidemiology Unit (MC_UU_00011/1, MC_UU_00011/4 and MC_UU_00011/7). This study was funded/supported by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol (GDS, TRG and REW). This study received funding from the UK Medical Research Council (MR/R013942/1). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. YMZ is supported by the National Natural Science Foundation of China (81800636) and Beijing Natural Science Foundation (7184253). HZ is supported by the Training Program of the Major Research Plan of the National Natural Science Foundation of China (91642120), the Grant from the Science and Technology Project of Beijing, China (D18110700010000) and the University of Michigan Health System Peking University Health Science Center Joint Institute for Translational and Clinical Research (BMU2017JI007). NF is supported by the National Institutes of Health awards R01-MD012765, R01-DK117445 and R21-HL140385. RC is funded by a Wellcome Trust GW4 Clinical Academic Training Fellowship (WT 212557/Z/18/Z). The Nord Trondelag Health Study (The HUNT Study) is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology), Nord Trondelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. MCB is supported by the UK Medical Research Council (MRC) Skills Development Fellowship (MR/P014054/1). SF is supported by a Wellcome Trust PhD studentship (WT108902/Z/15/Z). QY is funded by a China Scholarship Council PhD scholarship (CSC201808060273). YC was supported by the National Key R&D Program of China (2016YFC0900500, 2016YFC0900501, 2016YFC0900504). The China Kadoorie Biobank baseline survey and the first re-survey were supported by a grant from the Kadoorie Charitable Foundation in Hong Kong. The long-term follow-up is supported by grants from the UK Wellcome Trust (202922/Z/16/Z, 088158/Z/09/Z, 104085/Z/14/Z). Japan-Kidney-Biobank was supported by AMED under Grant Number 20km0405210. PCH is supported by Cancer Research UK [grant number: C18281/A19169]. AK was supported by DFG KO 3598/5-1. N.F. is supported by NIH awards R01-DK117445, R01-MD012765, R21-HL140385.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The paper only used summary stats from public domain so the ethnics approvals belong to the original GWAS studies
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵§ CKD MR working group
Data Availability
The genome-wide association analysis results of CKD and eGFR in the UK Biobank can be accessed via MR-Base (www.mrbase.org) and the IEU OpenGWAS database (gwas.mrcieu.ac.uk).
